The company's second-largest product, STELARA, is facing imminent competition from biosimilars in the U.S. and Europe. This expected revenue and market share erosion creates pressure to optimize costs and improve commercial effectiveness for other products to compensate for the loss.
Filing excerpt
Sales of the Company’s second largest product, STELARA (ustekinumab) accounted for approximately 6.5% of the Company's total revenues for fiscal 2025.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kmarketShareLossGet every 10-K signal for Johnson & Johnson and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/ee4c8ea6-35c2-4e7a-ae3b-d83927b6d2be returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.
{
"signal_id": "ee4c8ea6-35c2-4e7a-ae3b-d83927b6d2be",
"signal_type": "sec-10k",
"signal_subtype": "marketShareLoss",
"detected_at": "2026-02-17T06:28:56.417+00:00",
"company": {
"name": "Johnson & Johnson",
"domain": "jnj.com"
},
"data": {
"detail": "The company's second-largest product, STELARA, is facing imminent competition from biosimilars in the U.S. and Europe. This expected revenue and market share erosion creates pressure to optimize costs and improve commercial effectiveness for other products to compensate for the loss.",
"metrics": {
"pct": 0.065,
"pct_context": "of total revenues from STELARA"
},
"summary": "J&J expects negative sales impact on STELARA (6.5% of revenue) from global biosimilar launches.",
"excerpts": "Sales of the Company’s second largest product, STELARA (ustekinumab) accounted for approximately 6.5% of the Company's total revenues for fiscal 2025.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/28",
"sales_relevance": "Urgency to improve",
"signal_category": "market",
"regions_mentioned": [
"United States",
"Europe"
]
}
}
curl https://signals.autobound.ai/v1/signals/ee4c8ea6-35c2-4e7a-ae3b-d83927b6d2be \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.